Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, our influenza vaccine candidate, has unique characteristics that stimulate multiple arms of the immune system and offers the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine. By leveraging the complementary attributes of its proprietary technology platforms, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including both acute and chronic infections and cancer. Source
No articles found.
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Dova is a pharmaceutical company focused on acquiring, developing and commercializ...
Dova is a pharmaceutical company focused on acq...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
Join the National Investor Network and get the latest information with your interests in mind.